Canadian Journal of Infectious Diseases and Medical Microbiology / 2020 / Article / Tab 1

Research Article

Antimicrobial Susceptibility Testing of Metronidazole and Clindamycin against Gardnerella vaginalis in Planktonic and Biofilm Formation

Table 1

Minimum inhibitory concentration (MIC) and minimum biofilm eradication concentrations (MBEC) for Gardnerella vaginalis at the planktonic and biofilm levels.

Isolate no.Biofilm producerMetronidazoleClindamycin
Planktonic MIC (μg/mL)Biofilm MIC (μg/mL)MIC ratioaMBEC (μg/mL)Planktonic MIC (μg/mL)Biofilm MIC (μg/mL)MIC ratioaMBEC (μg/mL)

G1Moderate8162>1280.031213232
G2Strong16>1288>128≤0.0312>642048>64
G3Moderate284>128≤0.03120.5168
G4Moderate2>12864>128≤0.0312>642048>64
G5Moderate8>12816>128≤0.0312>64204832
G6Weak0.25>128512>128≤0.06250.516>64
G7Weak20.50.25>128≤0.06250.51632
G8Weak8>12816>1280.50.5132
G9Weak242>1280.1250.5432
G10Weak≤0.0625≤0.1252>1280.125188
Standard strainbModerate321284>128≤0.06250.5168

MIC breakpoints adapted and interpreted as sensitive, resistant, or intermediate as defined by CLSI criteria for metronidazole (sensitive: ≤8 μg/mL; intermediate: = 16 μg/mL; resistant: ≥32 μg/mL) and clindamycin (sensitive: ≤2 μg/mL; intermediate: = 4 μg/mL; resistant: ≥8 μg/mL) were used for interpreting MIC results; The aMIC ratio was calculated using the following formula: MIC value with biofilm formation/MIC value without biofilm formation; bGardnerella vaginalis ATCC®14018 was used as a quality control bacterium and cultivated under anaerobic conditions.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.